Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): Case reports from the SENTRY antimicrobial surveillance program

Kari C. Kugler, Gerald A. Denys, Michael L. Wilson, Ronald N. Jones

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The emergence and sustained prevalence of Gram-positive organisms resistant to antimicrobials has been of interest for over a decade. Quinupristin/dalfopristin (formerly RP 59500 or Synercid®) is a new injectable streptogramin combination that has been reported to have activity against Gram-positive organisms, even those with documented MLS(B) resistance. However, the two case reports presented here illustrate three well-documented Streptococcus spp. strains (S. mitis, S. pneumoniae) to be resistant to quinupristin/dalfopristin (MICs at 3, 8, and 12 μg/ml) following referral as routine isolates in the SENTRY Antimicrobial Surveillance Program. The S. pneumoniae pleural fluid isolate was cross-resistant to erythromycin. Both bacteremic S. mitis strains were resistant to macrolides (erythromycin, azithromycin, clarithromycin), lincosamides (clindamycin), and fluoroquinolones. Patient histories indicated no prior use of MLS class antimicrobials for the S. mitis case, but the patient having the S. pneumoniae isolate did receive prior treatment of erythromycin and clindamycin. All isolates had modestly increased penicillin MICs of 0.12 μg/ml. The mode of resistance to quinupristin/dalfopristin was not evident (sat A-negative by PCR); and these cases illustrate the existence of streptogramin-resistant isolates before the introduction of this antimicrobial class into human clinical practice. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)269-272
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume36
Issue number4
DOIs
StatePublished - Apr 1 2000

Fingerprint

Streptogramins
Streptococcal Infections
Erythromycin
Pneumonia
Clindamycin
Lincosamides
Azithromycin
Clarithromycin
Fluoroquinolones
Macrolides
Streptococcus
Penicillins
Referral and Consultation
quinupristin-dalfopristin
Polymerase Chain Reaction
Injections

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{8062088df20847fd90b46210cba16339,
title = "Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): Case reports from the SENTRY antimicrobial surveillance program",
abstract = "The emergence and sustained prevalence of Gram-positive organisms resistant to antimicrobials has been of interest for over a decade. Quinupristin/dalfopristin (formerly RP 59500 or Synercid{\circledR}) is a new injectable streptogramin combination that has been reported to have activity against Gram-positive organisms, even those with documented MLS(B) resistance. However, the two case reports presented here illustrate three well-documented Streptococcus spp. strains (S. mitis, S. pneumoniae) to be resistant to quinupristin/dalfopristin (MICs at 3, 8, and 12 μg/ml) following referral as routine isolates in the SENTRY Antimicrobial Surveillance Program. The S. pneumoniae pleural fluid isolate was cross-resistant to erythromycin. Both bacteremic S. mitis strains were resistant to macrolides (erythromycin, azithromycin, clarithromycin), lincosamides (clindamycin), and fluoroquinolones. Patient histories indicated no prior use of MLS class antimicrobials for the S. mitis case, but the patient having the S. pneumoniae isolate did receive prior treatment of erythromycin and clindamycin. All isolates had modestly increased penicillin MICs of 0.12 μg/ml. The mode of resistance to quinupristin/dalfopristin was not evident (sat A-negative by PCR); and these cases illustrate the existence of streptogramin-resistant isolates before the introduction of this antimicrobial class into human clinical practice. Copyright (C) 2000 Elsevier Science Inc.",
author = "Kugler, {Kari C.} and Denys, {Gerald A.} and Wilson, {Michael L.} and Jones, {Ronald N.}",
year = "2000",
month = "4",
day = "1",
doi = "10.1016/S0732-8893(00)00111-5",
language = "English (US)",
volume = "36",
pages = "269--272",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin)

T2 - Case reports from the SENTRY antimicrobial surveillance program

AU - Kugler, Kari C.

AU - Denys, Gerald A.

AU - Wilson, Michael L.

AU - Jones, Ronald N.

PY - 2000/4/1

Y1 - 2000/4/1

N2 - The emergence and sustained prevalence of Gram-positive organisms resistant to antimicrobials has been of interest for over a decade. Quinupristin/dalfopristin (formerly RP 59500 or Synercid®) is a new injectable streptogramin combination that has been reported to have activity against Gram-positive organisms, even those with documented MLS(B) resistance. However, the two case reports presented here illustrate three well-documented Streptococcus spp. strains (S. mitis, S. pneumoniae) to be resistant to quinupristin/dalfopristin (MICs at 3, 8, and 12 μg/ml) following referral as routine isolates in the SENTRY Antimicrobial Surveillance Program. The S. pneumoniae pleural fluid isolate was cross-resistant to erythromycin. Both bacteremic S. mitis strains were resistant to macrolides (erythromycin, azithromycin, clarithromycin), lincosamides (clindamycin), and fluoroquinolones. Patient histories indicated no prior use of MLS class antimicrobials for the S. mitis case, but the patient having the S. pneumoniae isolate did receive prior treatment of erythromycin and clindamycin. All isolates had modestly increased penicillin MICs of 0.12 μg/ml. The mode of resistance to quinupristin/dalfopristin was not evident (sat A-negative by PCR); and these cases illustrate the existence of streptogramin-resistant isolates before the introduction of this antimicrobial class into human clinical practice. Copyright (C) 2000 Elsevier Science Inc.

AB - The emergence and sustained prevalence of Gram-positive organisms resistant to antimicrobials has been of interest for over a decade. Quinupristin/dalfopristin (formerly RP 59500 or Synercid®) is a new injectable streptogramin combination that has been reported to have activity against Gram-positive organisms, even those with documented MLS(B) resistance. However, the two case reports presented here illustrate three well-documented Streptococcus spp. strains (S. mitis, S. pneumoniae) to be resistant to quinupristin/dalfopristin (MICs at 3, 8, and 12 μg/ml) following referral as routine isolates in the SENTRY Antimicrobial Surveillance Program. The S. pneumoniae pleural fluid isolate was cross-resistant to erythromycin. Both bacteremic S. mitis strains were resistant to macrolides (erythromycin, azithromycin, clarithromycin), lincosamides (clindamycin), and fluoroquinolones. Patient histories indicated no prior use of MLS class antimicrobials for the S. mitis case, but the patient having the S. pneumoniae isolate did receive prior treatment of erythromycin and clindamycin. All isolates had modestly increased penicillin MICs of 0.12 μg/ml. The mode of resistance to quinupristin/dalfopristin was not evident (sat A-negative by PCR); and these cases illustrate the existence of streptogramin-resistant isolates before the introduction of this antimicrobial class into human clinical practice. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034079627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034079627&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(00)00111-5

DO - 10.1016/S0732-8893(00)00111-5

M3 - Article

C2 - 10764970

AN - SCOPUS:0034079627

VL - 36

SP - 269

EP - 272

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -